Paroxysmal Nocturnal Hemoglobinuria - Causes, Symptoms, Diagnosis, and Treatment

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon blood disorder named after a specific symptom: the observation of red, brown, or dark urine during late-night or early-morning bathroom visits. The term "paroxysmal" indicates a sudden occurrence, "nocturnal" pertains to night, and "hemoglobinuria" denotes urine tinged with blood. The dark coloration of urine results from the immune system breaking down red blood cells, a process termed hemolysis by healthcare professionals. Dark-colored urine represents several PNH symptoms that could indicate potentially severe medical conditions. If left unaddressed, PNH may lead to hemolytic anemia, chronic kidney disease, or thrombosis (the formation of blood clots in blood vessels). Healthcare providers manage PNH by administering medications that deter damage to blood cells.

What Are the Causes of Paroxysmal Nocturnal Hemoglobinuria?

PNH occurs when a gene problem affects how the red blood cells and platelets function. This genetic issue sets off a series of events that can lead to severe and potentially life-threatening health problems. The process begins in the bone marrow, where the body produces stem cells that eventually become fully developed red blood cells, white blood cells, and platelets. In PNH, a gene called PIGA in one stem cell undergoes a mutation or change, turning it into an abnormal stem cell. This abnormal cell then multiplies and produces more abnormal stem cells, ultimately becoming abnormal red blood cells and platelets.

How Does Genetic Change Affect Red Blood Cells?

Occasionally, proteins that assist white blood cells in combating infections mistakenly target red blood cells. Healthcare providers term these proteins the complement system. Ordinary red blood cells possess a protective layer of proteins that shield them from complement system attacks. The PIGA gene is responsible for constructing this shield. When the PIGA gene undergoes a mutation, it ceases to produce these protective shields.

As the complement system assaults the red blood cells, they disintegrate, releasing hemoglobin. Hemoglobin aids red blood cells in transporting oxygen throughout the body. When red blood cells break apart, they release their hemoglobin, known as free hemoglobin, according to healthcare providers, into the bloodstream. Typically, a substance called haptoglobin steps in to clear out free hemoglobin. However, in PNH, the bloodstream's cleaning mechanism struggles to keep pace.

The body attempts to cope with the surplus by using nitric oxide, but this depletes the body's nitric oxide supply. Insufficient nitric oxide can lead to sudden, painful spasms in the stomach, esophagus, and back muscles. Simultaneously, the bone marrow faces pressure to produce more red blood cells to replace those destroyed by the complement system. Anemia occurs when the bone marrow cannot generate sufficient red blood cells to compensate for the ones destroyed.

The excess hemoglobin also harms the kidneys, increasing the risk of chronic kidney disease for individuals with PNH, who are six times more likely to develop this condition. Free hemoglobin also affects urine color. Many individuals with PNH observe dark-colored urine at night or in the morning. This occurs because excess hemoglobin concentrates in the urine, turning it dark.

What Are the Symptoms of Paroxysmal Nocturnal Hemoglobinuria?

Paroxysmal nocturnal hemoglobinuria gets its name from a specific symptom, but individuals with PNH usually consult healthcare professionals due to intense and lasting fatigue impacting their daily activities. Additional symptoms include:

• Difficulty breathing (dyspnea).

• Issues with the kidneys.

• Challenges in swallowing (dysphagia).

• Esophageal spasms.

• Abdominal pain.

• Back pain.

• Erectile dysfunction.

What Is the Diagnostic Procedure for Paroxysmal Nocturnal Hemoglobinuria?

Healthcare professionals may employ various tests to detect indications of PNH. Based on these test outcomes, they might utilize flow cytometry to scrutinize the blood cells. Some of the tests healthcare providers could use include:

• Complete Blood Count With Differential (CBC W/Diff): This test helps identify signs of blood disorders such as anemia and thrombocytopenia.

• Basic Metabolic Panel (BMP): This test looks for indications of chronic kidney disease and renal dysfunction.

• Urinalysis: This examination can reveal hemoglobinuria (blood in urine) and hemosiderosis (excessive iron deposits).

• Reticulocyte Count: Measuring the number of immature red blood cells (reticulocytes) in the bone marrow helps healthcare providers determine if the bone marrow produces enough healthy red blood cells.

• Haptoglobin Test: Haptoglobin is a protein that clears debris from damaged red blood cells. Low levels may indicate damaged red blood cells.

• Lactate Dehydrogenase (LDH): LDH is an enzyme in red blood cells. Elevated LDH levels may signify increased destruction of red blood cells.

• Liver Function: This test assesses bilirubin levels, which can rise when red blood cells break down.

What Is the Treatment for Paroxysmal Nocturnal Hemoglobinuria?

Treatment for paroxysmal nocturnal hemoglobinuria (PNH) mainly focuses on symptom management. Medications can be prescribed to prevent blood clots, boost red blood cell count, and address other potential issues. However, it is important to note that a stem cell transplant is the only known cure for PNH, although it carries some risks. The choice of treatment depends on the severity of the symptoms. If the symptoms are mild and not bothersome, one may not require immediate treatment. The doctor will monitor the patient for symptoms over time. Treatment will be initiated if one experiences issues such as bruising, bleeding, fatigue, or shortness of breath.

• Medicinal Treatment: The primary treatment for PNH involves medications aimed at preventing the breakdown of red blood cells, reducing the risk of blood clots, and enhancing overall quality of life. Eculizumab and Ravulizumab function similarly and are administered through intravenous (IV) infusion. Soliris is typically given every two weeks, while Ravulizumab is administered every eight weeks. While Eculizumab and Ravulizumab effectively manage symptoms, it is important to note that they do not provide a cure for PNH. Continuous medication is necessary for the entirety of one's life or until the disease enters a state of remission.

For those newly starting treatment or transitioning from Eculizumab and Ravulizumab, Pegcetacoplan is a targeted therapy. Administered through IV infusion, it is taken twice a week. It is essential to be aware that these medications, by partially blocking the immune system, may increase the risk of serious infections before starting Eculizumab or Ravulizumab. It is recommended to receive the meningococcal vaccine at least two weeks before the first dose. Regular monitoring for signs of infection will be conducted while on these medications, and some individuals may require Penicillin prophylaxis.

• Stem Cell Transplant: Stem cells, the early cells in bone marrow that develop into new blood cells, are crucial in treating PNH. An allogeneic stem cell transplant, also known as a bone marrow transplant, is the sole cure for PNH. This procedure involves replacing damaged stem cells with healthy ones from a donor, typically a close relative because they are often the best match. However, the transplant carries serious risks, including infections and potential organ damage, making it suitable only for those with severe PNH at risk of life-threatening blood clots or other serious complications.

Before the transplant, the body undergoes preparations for the new cells. Chemotherapy or radiation eliminates the old and damaged bone marrow, creating space for the new stem cells to flourish. These stem cells are introduced into the body through a thin tube placed in the chest or neck. Once in the bone marrow, they mature into healthy new blood cells.

Conclusion

In conclusion, Paroxysmal Nocturnal Hemoglobinuria (PNH) poses a significant threat to individuals due to its potential to lead to severe complications such as hemolytic anemia, chronic kidney disease, and thrombosis. The genetic mutation affecting the PIGA gene results in the breakdown of red blood cells, causing dark urine and a range of debilitating symptoms. The diagnostic process involves various tests, and while medications like Eculizumab and Ravulizumab manage symptoms, a stem cell transplant remains the only known cure, albeit with substantial risks.